Super-pharm sales leap to NIS 2.65b. in 2006

Super-pharm posted its largest sales gain in seven years in 2006, generating revenues of NIS 2.65 billion, a six percent increase over 2005 levels.

By SHARON WROBEL
December 19, 2006 07:45

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Super-pharm posted its largest sales gain in seven years in 2006, generating revenues of NIS 2.65 billion, a six percent increase over 2005 levels. "Despite the war in the North and the security situation this year, we achieved record sales this year and we expect to reach a target of NIS 2.9b. in sales in 2007," said Lior Reitblatt, President & CEO of Super-pharm. In 2006, the chain opened nine new branches, of which six were in the periphery and the Arab sector. Next year, Super-pharm plans to open 15 new branches extending its presence in these areas. Over the next three years, Super-pharm plans to focus on extending its activity in Poland as well as in China, where the chain recently purchased the Ensure pharmacy chain. In Poland, the company anticipates expanding its presence from the current 14 branches, which generated $40 million in revenues this year, to 50 branches by 2010.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS